ACROBiosystems has announced a significant upgrade to its global licensing solution for HEK293 functional cell lines, a move poised to…
Read More
FDA Issues Landmark Guidance to Enhance Pregnancy Safety Data for Medications
The US Food and Drug Administration (FDA) has unveiled its comprehensive final guidance for industry on collecting crucial post-marketing safety…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
Ginkgo Bioworks CEO Jason Kelly Discusses Autonomous Labs and the Future of Biopharma R&D
The landscape of biopharmaceutical research and development (R&D) is undergoing a seismic shift, driven by the integration of advanced robotics…
Read More
The Evolving Role of Vitamin E TPGS in Advanced Parenteral Drug Delivery
For decades, d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), a derivative of vitamin E, has been a cornerstone in oral drug…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Paradigm Health eSource Casebook Revolutionizes Clinical Trial Data Management, Addressing Industry-Wide Challenges
The landscape of clinical trials is undergoing a significant transformation, driven by increasingly complex protocols and the escalating demands placed…
Read More
Novartis Breaks Ground on New Radioligand Therapy Manufacturing Facility in Denton, Texas, Bolstering US Healthcare Infrastructure
Novartis has commenced construction on a significant new radioligand therapy (RLT) manufacturing facility in Denton, Texas, a pivotal development in…
Read More
The Autonomous Revolution: How Ginkgo Bioworks is Driving a Paradigm Shift in Biopharma R&D
The biopharmaceutical industry, long reliant on the meticulous, hands-on work of human researchers, is on the cusp of a profound…
Read More
Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches
Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…
Read More
